Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
2009/01/01 by Oliver D. Howes, Oliver Howes, Andrew Montgomery +17 · 33 citations
Medicine · Neuroscience · Psychology · #Schizophrenia research and treatment #Neurotransmitter Receptor Influence on Behavior #Psychopathy, Forensic Psychiatry, Sexual Offending
paper · doi:10.1001/archgenpsychiatry.2008.514
Abstract
CONTEXT: A major limitation on the development of biomarkers and novel interventions for schizophrenia is that its pathogenesis is unknown. Although elevated striatal dopamine activity is thought to be fundamental to schizophrenia, it is unclear when this neurochemical abnormality develops in relation to the onset of illness and how this relates to the symptoms and neurocognitive impairment seen in individuals with prodromal symptoms of schizophrenia. OBJECTIVES: To determine whether striatal dopamine function is elevated in individuals with prodromal symptoms of schizophrenia before the onset of psychosis and to assess how this relates to the symptoms and neurocognitive impairment. DESIGN: Case-control study of in vivo striatal dopaminergic function. SETTING: Academic research. Patients Patients were recruited from a community mental health service. Twenty-four patients having prodromal symptoms of schizophrenia were compared with 7 patients having schizophrenia and with 12 matched healthy control subjects from the same community. Main Outcome Measure Striatal 6-fluoro-l-dopa F 18-dopa uptake measured using positron emission tomographic (18)F-dopa imaging. RESULTS: Striatal (18)F-dopa uptake was elevated in patients with prodromal symptoms of schizophrenia (effect size, 0.75) to an intermediate degree compared with that in patients with schizophrenia (effect size, 1.25). The elevation was localized in the associative striatum in both groups. Moreover, striatal (18)F-dopa uptake in patients with prodromal symptoms of schizophrenia was correlated with the severity of prodromal psychopathologic and neuropsychological impairment but not with the severity of anxiety or depressive symptoms. CONCLUSIONS: These findings indicate that dopamine overactivity predates the onset of schizophrenia in individuals with prodromal psychotic symptoms, is predominantly localized in the associative striatum, and is correlated with the severity of symptoms and neurocognitive dysfunction.
Cited by
- Integrative Brain Network and Salience Models of Psychopathology and Cognitive Dysfunction in Schizophrenia
- An Integrative Perspective on the Role of Dopamine in Schizophrenia
- Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms
- Dopaminergic basis of salience dysregulation in psychosis
- Reward Processing in Mood Disorders and Schizophrenia: A Neurodevelopmental Framework
- Schizophrenia and disordered sensorimotor control: challenges, mechanisms and opportunities
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
- Spontaneous Brain Activity Alterations in First-Episode Psychosis: A Meta-analysis of Functional Magnetic Resonance Imaging Studies
- Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. [europepmc]
- Executive function, neural circuitry, and genetic mechanisms in schizophrenia. [europepmc]
- A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. [europepmc]
- Toward a neurobiology of delusions. [europepmc]
- Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. [europepmc]
- Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. [europepmc]
- Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. [europepmc]
- The nature of dopamine dysfunction in schizophrenia and what this means for treatment. [europepmc]
- The psychosis high-risk state: a comprehensive state-of-the-art review. [europepmc]
- Stress and neurodevelopmental processes in the emergence of psychosis. [europepmc]
- Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. [europepmc]
- Schizophrenia: an integrated sociodevelopmental-cognitive model. [europepmc]
- Glutamate and dopamine in schizophrenia: an update for the 21st century. [europepmc]
- How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis. [europepmc]
- A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. [europepmc]
- Pathway-Specific Dopamine Abnormalities in Schizophrenia. [europepmc]
- An Integrative Perspective on the Role of Dopamine in Schizophrenia. [europepmc]
- The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. [europepmc]
- The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. [europepmc]
- A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. [europepmc]
- Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. [europepmc]
- Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. [europepmc]
- Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. [europepmc]
- The Role of Estrogen in Brain and Cognitive Aging. [europepmc]
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. [europepmc]
Related